Sun Pharma Buys GSK’s Opiates Business in Australia

Published: 04th March 2015 06:05 AM  |   Last Updated: 04th March 2015 06:05 AM   |  A+A-

HYDERABAD: The country’s largest drugmaker by market value, Sun Pharma Ltd, on Tuesday said it will acquire GlaxoSmithKline’s (GSK) Opiates business in Australia for an undisclosed sum.

For Dilip Shanghvi-led Sun, which already has 17 acquisitions under its belt including the high-profile Ranbaxy Laboratories, the acquisition will strengthen its portfolio of opiates in Australia.

For GSK, the deal will allow it to simplify its operations in Australia and focus on its product portfolio central to its growth strategy in Australia.

GSK’s Opiates business product portfolio consists of poppy-derived opiate raw materials that are primarily used in the manufacture of analgesics for the treatment of moderate to severe pain.

sun.JPG“The acquisition is a part of our strategy towards building our portfolio of opiates and accessing strong capabilities in this segment,” said Iftach Seri, Executive Vice President, API business, Sun Pharma.

He added that the global opiates market holds good potential and the addition of GSK’s Opiates business will strengthen the company’s positioning further. As per the agreement, GSK will transfer manufacturing sites in Latrobe (Tasmania) and Port Fairy (Victoria) and its portfolio of opiates products along with inventory, to a subsidiary of Sun Pharma.

The transaction is expected to close by August, 2015 subject to customary closing conditions and requisite regulatory approvals. Employees from both sites will also be offered employment by Sun with the Opiates business.

“The Opiates business has been an important part of our Australian business for many years, but as our portfolio transitions, we believe now is the right time to hand this business over to someone else,” said Steve Morris, General Manager, GSK Opiates.


Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on are those of the comment writers alone. They do not represent the views or opinions of or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp